Lyka Labs Ltd

Lyka Labs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Lyka Labs Ltd

₹ 118 0.72%
11 Jun - close price
lykalabs.com BSE: 500259 NSE: LYKALABS
About

Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]

Key Points

Business Overview:[1]
LLL is a WHO-GMP certified and ISO 9001- certified manufacturer of Pharmaceutical Formulations & Active Pharmaceutical Ingredients across various therapeutic segments, including Lyophilized injections, topical formulations of cream, ointment, foams, gels & lotions.

Website BSE NSE
  • Market Cap ₹ 419 Cr.
  • Current Price ₹ 118
  • High / Low ₹ 177 / 90.2
  • Stock P/E 50.9
  • Book Value ₹ 37.8
  • Dividend Yield 0.00 %
  • ROCE 8.31 %
  • ROE 7.03 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.

Cons

  • Stock is trading at 3.11 times its book value
  • Company has a low return on equity of -0.12% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
27.68 21.88 22.13 17.13 19.46 21.24 26.76 31.42 26.98 30.10 41.16 32.92 30.52
16.12 15.96 17.40 14.91 16.73 18.69 22.82 25.56 24.76 26.05 35.82 27.83 27.11
Operating Profit 11.56 5.92 4.73 2.22 2.73 2.55 3.94 5.86 2.22 4.05 5.34 5.09 3.41
OPM % 41.76% 27.06% 21.37% 12.96% 14.03% 12.01% 14.72% 18.65% 8.23% 13.46% 12.97% 15.46% 11.17%
-2.14 0.68 0.90 -5.79 0.47 0.43 0.25 0.52 0.38 0.62 0.13 0.87 0.72
Interest 2.91 2.80 2.91 3.04 2.81 1.33 1.17 1.26 1.04 0.65 0.52 0.62 0.52
Depreciation 9.13 3.41 3.46 3.33 3.32 3.34 3.46 2.72 2.77 1.68 1.68 1.75 1.34
Profit before tax -2.62 0.39 -0.74 -9.94 -2.93 -1.69 -0.44 2.40 -1.21 2.34 3.27 3.59 2.27
Tax % 481.30% 15.38% -45.95% 2.82% 2.39% 2.37% -34.09% 43.33% 33.06% 25.64% 24.16% 24.79% 42.73%
-15.24 0.33 -0.40 -10.21 -3.01 -1.72 -0.29 1.36 -1.62 1.75 2.47 2.70 1.31
EPS in Rs -5.31 0.12 -0.14 -3.56 -0.98 -0.52 -0.09 0.41 -0.49 0.49 0.69 0.76 0.37
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Jun 2014 15m Jun 2015 Mar 2016 9m Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
87 90 57 78 42 41 41 62 164 81 106 135
88 72 49 56 42 40 44 48 67 65 92 117
Operating Profit -2 18 8 22 -1 1 -3 14 98 16 15 18
OPM % -2% 20% 14% 28% -1% 2% -8% 23% 59% 19% 14% 13%
24 5 11 -0 3 2 -25 1 -2 -4 2 2
Interest 24 18 11 17 8 6 19 26 20 12 5 2
Depreciation 5 4 3 6 6 4 8 8 15 14 12 6
Profit before tax -7 1 5 -1 -11 -7 -55 -18 60 -13 -1 11
Tax % 0% 0% 0% -66% -3% -124% 0% -21% 34% 1% 143% 28%
-7 1 5 -0 -11 2 -55 -14 40 -13 -2 8
EPS in Rs -3.37 0.63 2.19 -0.09 -3.85 0.61 -19.31 -5.04 13.91 -4.33 -0.69 2.31
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 5%
5 Years: 27%
3 Years: -6%
TTM: 27%
Compounded Profit Growth
10 Years: 9%
5 Years: 18%
3 Years: -42%
TTM: 456%
Stock Price CAGR
10 Years: 7%
5 Years: 47%
3 Years: -4%
1 Year: 10%
Return on Equity
10 Years: 0%
5 Years: 10%
3 Years: 0%
Last Year: 7%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 22 22 22 22 28 28 29 29 29 31 33 36
Reserves 40 38 43 52 69 70 -10 -24 16 46 66 99
140 109 106 112 102 91 137 163 129 74 59 38
61 64 57 57 46 59 66 46 35 28 28 32
Total Liabilities 263 233 228 243 245 249 221 213 209 179 186 206
94 62 60 86 81 76 102 95 90 66 56 85
CWIP 22 27 30 24 26 30 26 24 18 16 23 0
Investments 63 63 63 62 62 62 32 32 32 32 32 32
84 82 75 70 75 80 61 61 68 65 75 88
Total Assets 263 233 228 243 245 249 221 213 209 179 186 206

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
55 29 8 20 7 18 -11 6 77 7 3 3
-25 30 5 -5 -3 -3 0 0 -4 7 -9 -13
-29 -63 -13 -15 -4 -16 20 -8 -63 -20 3 5
Net Cash Flow 2 -3 0 -0 -1 -0 8 -2 9 -7 -3 -5

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 107 116 169 113 265 263 59 58 39 78 88 110
Inventory Days 58 90 74 93 124 98 99 67 97 87 81 86
Days Payable 235 283 323 283 536 519 430 301 109 103 93 95
Cash Conversion Cycle -70 -77 -80 -76 -147 -159 -272 -176 26 62 77 100
Working Capital Days -153 -167 -196 -222 -456 -62 -201 -90 11 55 78 107
ROCE % -1% 9% 9% 10% -3% -0% -5% 5% 50% 3% 3% 8%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
47.80% 47.58% 47.58% 51.00% 54.58% 54.81% 54.81% 54.81% 58.11% 58.11% 58.11% 58.16%
0.76% 0.57% 0.37% 0.18% 0.17% 0.18% 0.17% 0.17% 0.15% 0.15% 0.15% 0.24%
3.99% 4.00% 4.00% 3.74% 0.41% 0.41% 0.62% 0.81% 0.75% 0.66% 0.66% 0.66%
47.45% 47.85% 48.05% 45.08% 44.84% 44.61% 44.41% 44.21% 40.99% 41.08% 41.07% 40.93%
No. of Shareholders 26,96928,43328,51526,82027,20226,65226,42225,71725,71628,94329,09928,472

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings